https://nova.newcastle.edu.au/vital/access/ /manager/Index en-au 5 https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:42678 Wed 31 Aug 2022 16:53:30 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:48700 Wed 29 Mar 2023 11:35:00 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:51026 Wed 28 Feb 2024 16:13:12 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:51366 Wed 28 Feb 2024 15:46:29 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:45438 Wed 20 Mar 2024 15:45:49 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:32651 30 kg/m²). Exacerbations requiring medical intervention were recorded prospectively. Asthma control, medication use, and fractional exhaled nitric oxide were assessed monthly; additional visits occurred during exacerbations. Peripheral blood was collected at baseline for the measurement of eosinophils, soluble CD-163, C-reactive protein, and IL-6. Results: Exacerbations occurred in a higher proportion of overweight (51.1%) and obese (48.4%) women compared with healthy weight women (25%; P =.026). Excess weight gain during pregnancy was not associated with exacerbation risk. Macrophage activation (elevated serum soluble CD-163) was associated with exacerbations requiring oral corticosteroids (P =.043), whereas high peripheral blood eosinophils or fractional exhaled nitric oxide were not associated with exacerbation or oral corticosteroid use. Conclusions: Being overweight or obese confers a greater risk of asthma exacerbation during pregnancy, and may be due to systemic macrophage activation.]]> Wed 19 Jan 2022 15:19:04 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:14520 Wed 11 Apr 2018 16:28:20 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:22224 Wed 11 Apr 2018 13:02:09 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:13797 Wed 11 Apr 2018 11:18:00 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:19199 Wed 11 Apr 2018 10:44:57 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:32663 Wed 10 Nov 2021 15:04:16 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:33937 interaction=0·25). p values for interaction for all other subgroup analyses were also higher than 0·05; therefore, we did not show that the effects of this intervention are stronger in any one subgroup than in another. Six studies were assessed as being at low risk of bias, and one was assessed as being at unclear risk of bias. The two-step meta-analysis did not reveal evidence of heterogeneity of effect (I²=0·0, p=0·56). Interpretation: Vitamin D supplementation reduced the rate of asthma exacerbations requiring treatment with systemic corticosteroids overall. We did not find definitive evidence that effects of this intervention differed across subgroups of patients. Funding: Health Technology Assessment Program, National Institute for Health Research (reference number 13/03/25).]]> Wed 06 Apr 2022 14:01:37 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:30679 n = 17; age 10.7 (2.4) years) and without asthma (n = 17; age 10.8 (2.3) years), referred for overnight polysomnography, underwent measurement of lung function, plasma appetite hormones, dietary intake and food cravings, activity, and daytime sleepiness. Sleep latency (56.6 (25.5) vs. 40.9 (16.9) min, p = 0.042) and plasma triglycerides (1.0 (0.8, 1.2) vs. 0.7 (0.7, 0.8) mmol/L, p = 0.013) were significantly greater in asthmatic versus non-asthmatic children. No group difference was observed in appetite hormones, dietary intake, or activity levels (p > 0.05). Sleep duration paralleled overall diet quality (r = 0.36, p = 0.04), whilst daytime sleepiness paralleled plasma lipids (r = 0.61, p =0.001) and sedentary time (r = 0.39, p = 0.02). Disturbances in sleep quality and plasma triglycerides were evident in non-obese asthmatic children referred for polysomnography, versus non-asthmatic children. Observed associations between diet quality, sedentary behavior, and metabolic and sleep-related outcomes warrant further investigation, particularly the long-term health implications.]]> Wed 02 Oct 2019 10:15:41 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:43636 Tue 27 Sep 2022 09:39:17 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:39820 Tue 26 Jul 2022 11:33:21 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:38233 Tue 17 Aug 2021 08:35:47 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:47084 Tue 13 Dec 2022 16:35:23 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:46987 Tue 13 Dec 2022 09:28:47 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:39670 Thu 28 Jul 2022 08:10:20 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:45342 Thu 27 Oct 2022 15:17:41 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:37883 Thu 24 Aug 2023 16:08:54 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:48625 p = .04). Infant acute-care presentations (45 versus 13%, p = .02) and oral corticosteroid use (26 versus 4%, p = .03) due to “asthma/wheezing” were higher in the maternal group with 25(OH)D < 75 nmol/L, versus ≥75 nmol/L. Conclusions: Most pregnant women with asthma had low vitamin D status, which persisted across gestation. Low maternal vitamin D status was associated with greater risk of adverse respiratory outcomes in their infants, a group at high risk of developing childhood asthma.]]> Thu 23 Mar 2023 18:39:19 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:45174 versus non-exacerbators. Conclusion: Maternal asthma exacerbations increase the risk of SGA and caesarean sections, particularly in women with multiple exacerbations or moderate–severe asthma. Adequate antenatal asthma care is needed to reduce exacerbations and reduce risks of poor outcomes.]]> Thu 23 Mar 2023 14:01:19 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:48967 Thu 20 Apr 2023 10:09:50 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:25524 29 parts per billion (ppb), decrease in dose when FENO <19 ppb, and no change when FENO is between 19 and 29 ppb). A long acting beta agonist (LABA) will be added when symptoms remain uncontrolled. Both the control and intervention groups will report on exacerbations at a postpartum phone interview. The primary outcome is adverse perinatal outcome (a composite measure including preterm birth, intrauterine growth restriction, neonatal hospitalisation at birth or perinatal mortality), assessed from hospital records. Secondary outcomes will be each component of the primary outcome, maternal exacerbations requiring medical intervention during pregnancy (both smokers and non-smokers), and hospitalisation and emergency department presentation for wheeze, bronchiolitis or croup in the first 12 months of infancy. Outcome assessment and statistical analysis of the primary outcome will be blinded. To detect a reduction in adverse perinatal outcomes from 35 % to 26 %, 600 pregnant women with asthma per group are required. Discussion: This trial will provide evidence for the effectiveness of a FENO-based management strategy in improving perinatal outcomes in pregnant women with asthma. If successful, this would improve the management of pregnant women with asthma worldwide.]]> Thu 17 Mar 2022 14:41:14 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:50895 Thu 10 Aug 2023 10:29:50 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:14522 Sat 24 Mar 2018 08:19:45 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:14524 Sat 24 Mar 2018 08:19:45 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:14509 Sat 24 Mar 2018 08:19:42 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:16025 0.05). In the online group there was an increase in %energy from core foods and decrease in %energy from energy-dense nutrient-poor foods (P < 0.05) that was significantly different compared to controls at 3 and 6 months (P < 0.05). Conclusion: Results suggest that men randomised to the SHED-IT intervention arms were able to implement key dietary messages up to 6 months compared to controls. Future interventions should include targeted and gender-tailored messages as a strategy to improve men's dietary intake within weight loss interventions.]]> Sat 24 Mar 2018 08:19:30 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:26767 Sat 24 Mar 2018 07:24:45 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:39780 Mon 25 Jul 2022 11:26:17 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:53947 Mon 24 Jun 2024 15:59:20 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:49544 Mon 22 May 2023 08:45:35 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:42352 0.2). Preeclampsia was more common in the low (8.6%) vs. high (0%) vitamin D group (p < 0.05). Obesity and excess GWG may be associated with gestational 25(OH)D levels, highlighting the importance of antenatal weight management.]]> Mon 22 Aug 2022 14:01:38 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:42045 N = 895). Medication use, adherence, knowledge, and inhaler technique were compared between cohorts. Changes in self-management knowledge/skills and women's perception of medication risk to the fetus were assessed in 685 women with 5 assessments during pregnancy, and 95 women who had a postpartum assessment. RESULTS:At study entry, 41%, 29%, and 38% of participants used ICS in the 2004, 2007, and 2013 cohorts, respectively (p = 0.017), with 40% non-adherence in each cohort. Self-management skills of pregnant women with asthma did not improve between 2004 and 2017 and possession of a written action plan remained low. Maximum improvements were reached by 3 sessions for medications knowledge and one session for inhaler technique, and were maintained postpartum. ICS adherence was maximally improved after one session, but not maintained postpartum. Perceived risk of asthma medications on the fetus was highest for corticosteroid-containing medication; and was significantly reduced following education. Conclusions: There was a high prevalence of non-adherence and poor self-management skills in all cohorts. More awareness of the importance of optimal asthma management during pregnancy is warranted, since no improvements were observed over the past decade.]]> Mon 22 Aug 2022 10:25:31 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:37007 ENO and symptoms (F_ENO group). Exacerbations were recorded prospectively. Height and weight were measured at baseline, and in late pregnancy. GWG was categorized according to Institute of Medicine guidelines. A validated parent-completed questionnaire assessed infant wheeze-related outcomes. Results: F_ENO-based management was associated with a significantly lower incidence rate ratio for maternal exacerbations in nonobese mothers (0.52, 95% confidence interval [CI], 0.31-0.88, P = .015, n = 129), and women with GWG within recommendations (0.35, 95% CI, 0.12-0.96, P = .042, n = 43), but not for obese mothers (0.59, 95% CI, 0.32-1.08, P = .089, n = 88), or women with excess GWG (0.58, 95% CI, 0.32-1.04, P = .07, n = 104). Recurrent bronchiolitis occurred in 5.3% (n = 1) of infants born to non-overweight mothers, 16.7% (n = 3) of infants of overweight mothers, and 21.7% (n = 5) of infants of obese mothers in the control group. In the F_ENO group, 2 infants of obese mothers had recurrent bronchiolitis (7.1%, P = .031). Conclusions: The benefits of F_ENO-based management are attenuated among obese mothers and those with excess GWG, indicating the importance of weight management in contributing to improved asthma management in pregnancy.]]> Mon 14 Nov 2022 20:28:20 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:50981 Mon 14 Aug 2023 15:39:12 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:44185 Mon 10 Oct 2022 10:55:30 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:40099 χ² tests and logistic regression models, adjusting for confounders, were utilized. Data were complete for 605 participants at T1 and 486 (80%) at T2. Of 605 participants: 89% initiated breastfeeding and 38% breastfed for more than 6 months. Breastfeeding for more than 6 months vs “never” was associated with a reduced adjusted relative risk of infant wheeze at T1 (0.54, 95% confidence interval, 0.30‐0.96). Bronchiolitis risk was reduced at T1 and T2 with more than 6 months of breastfeeding vs “never.” Breastfeeding duration of 1 to 3 months, 4 to 6 months, and more than 6 months were associated with a reduced risk of infant healthcare utilization (all P < .05, vs “never”), but not medication use (P > .05). Breastfeeding for more than 6 months was associated with a reduced risk of wheeze, bronchiolitis, and wheeze‐related healthcare utilization in infants at risk due to maternal asthma. Notably, breastfeeding for shorter durations was associated with a reduced risk of healthcare utilization compared with none. Larger cohorts are needed to further examine the impact of breastfeeding exposure on respiratory health in infants exposed to maternal asthma.]]> Mon 06 May 2024 11:07:39 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:41293 Mon 01 Aug 2022 12:02:30 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:33965 Fri 25 Jan 2019 14:42:22 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:17857 Fri 19 Jun 2015 15:04:57 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:39682 Fri 17 Jun 2022 15:46:08 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:39970 Fri 15 Jul 2022 10:18:15 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:44479 Fri 14 Oct 2022 08:50:25 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:47321 Fri 13 Jan 2023 11:06:47 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:46047 Fri 11 Nov 2022 14:11:12 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:50204 Fri 07 Jul 2023 10:17:32 AEST ]]>